Advanced Filters
noise

Jinan, China Clinical Trials

A listing of Jinan, China clinical trials actively recruiting patients volunteers.

Found 360 clinical trials
P Ping Li, Master

Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis

Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial ischemia. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of …

18 - 79 years of age All Phase N/A

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

To evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of Disitamab Vedotin(DV, RC48-ADC) intravenously combined with radiotherapy in the treatment of locally advanced solid tumors with HER2 expression

18 years of age All Phase 1
J Jing Zhang, Docter

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).

18 - 65 years of age All Phase 1
B Beihua Kong, Doctor

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

This is an open-label, two-part study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with a gynaecological malignancies.

18 - 75 years of age Female Phase 2
J Jiandong Zhang

Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC

To observe the efficacy and safety of adebelizumab combined with chemotherapy and sequential adebelizumab combined with radiotherapy in the treatment of newly diagnosed extensive small cell lung cancer.

18 - 75 years of age All Phase 2
Q Qun Lv, MD

Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity. Studies from cystic fibrosis suggest that eradication therapy aimed at PA can successfully transition patients to a culture-negative status, providing long-term benefits. Current guidelines for managing bronchiectasis …

18 - 80 years of age All Phase 4

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk …

25 - 80 years of age All Phase N/A
H Hongchen Wang

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors. The primary hypothesis of this study is that subjects will have a better objective response rate (ORR) when treated with …

18 years of age All Phase 1/2
X Xi Zhang

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation profiles and somatic mutations. The clinical treatment of ESC also refers to the treatment model of HGSOC. The PARP inhibitor niraparib used …

18 years of age Female Phase 2
J Junyuan Qi, MD. PHD

Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

This is a multicenter, single-arm, open, dose-escalation Phase I/II clinical trial, consisting of a dose-escalation phase (accelerated titration phase, 3+3 design) and a dose expansion phase.

18 years of age All Phase 1/2

Simplify language using AI